Bloomberg, September 13, 2016. The U.S. Food and Drug Administration has a message for doctors: The money you’re taking from pharmaceutical companies may be clouding your judgment. NCHR president Dr. Diana Zuckerman points out questions about the accuracy of safety data submitted by Pfizer about Chantix, the smoking cessation drug.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Medical Devices Approved Using Low-Quality Data Affect Medicare Costs
Bloomberg BNA, September 8, 2016. High-risk medical devices are sometimes approved using low-quality clinical data and this increases Medicare costs, a member of a Medicare congressional advisory panel said Sept. 8. “I agree completely” says Dr. Diana Zuckerman of NCHR
Read More »The ‘Grassroots Campaign’ for ‘Female Viagra’ Was Actually Funded by Its Manufacturer
New York Magazine’s The Cut, September 8, 2016. The “It” drug was Addyi, Sprout Pharmaceutical’s answer to low libido in women, approved by the FDA last August and now in the news for its low sales and for turning out to be a bit of a dud, effectiveness-wise.
Read More »I-Team: Company Behind EpiPen Fought to Keep Cheaper Generic Off Market
NBC4 New York, August 31, 2016. The CEO of Mylan Pharmaceuticals announced the launch of its own cheaper version of the EpiPen but previously fought to keep prices high by limiting options.
Read More »Part D Pricing Trends
POLITICO Prescription Pulse, August 22, 2016. Medtronic is facing allegations that it promoted a device for uses not approved by FDA. “If the device had been tested in a clinical trial it would have been clear that it was designed to fit a part of the spine the company wasn’t seeking approval for,” Diana Zuckerman of the National Center for Health Research explained to STAT.
Read More »